Gene pharmacotherapy Inoperable patients with chronic lower limb ischemia
| Autor: | Sergey L. Kiselev, N.D. Mzhavanadze, R. V. Deev, A. A. Isaev, R E Kalinin, Shval'b Pg, S V Gryaznov |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Lower limb ischemia business.industry Genetic enhancement Ischemia Blood flow medicine.disease Intermittent claudication Surgery Vascular endothelial growth factor Walking distance chemistry.chemical_compound Pharmacotherapy chemistry Internal medicine medicine Cardiology medicine.symptom business |
| Zdroj: | I.P. Pavlov Russian Medical Biological Herald. 19:28-37 |
| ISSN: | 2500-2546 0204-3475 |
| DOI: | 10.17816/pavlovj2011428-37 |
| Popis: | The article presents the results of the comparative six-month surveillance inoperable patients with atherosclerosis of lower extremities with clinical manifestations in the form of intermittent claudication (IIa-III century. AVPokrovskii to Fontaine), which are composed of conservative therapy received the drug genterapevtichesky "Neovaskulgen", a plasmid with the gene structure of vascular endothelial growth factor. The study included 50 patients (35 – in the clinical group and 15 – in the control group). The drug was administered intramuscularly, as close as possible to areas of ischemia, twice, at doses of 1.2 mg, with an interval of 14 days. Patients kontralirovlai: the length of pain-free walking distance, ankle-brachial index, transcutaneous oxygen napryazhdenie determined, the linear velocity of blood flow in the affected segment. It is established that in the clinical group were significantly increasing the length of pain-free walking distance, the linear velocity krovtoka. To a lesser extent the other indicators are growing. In the control group had deterioration of patients. The obtained results show the effectiveness of the drug "Neovaskulgen." |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|